EGFR and prostate carcinoma: For example, MerTK is involved in epidermal growth factor receptor (EGFR) inhibitor resistance in non-small-cell lung cancer [15], and blocking phagocytic receptors with the membrane-linked protein V can effectively slow tumor progression in prostate cancer [16].